Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MPI-485520
- Development stage
- Unknown
- Lead developer
- Myrexis
- Modality
- Small Molecules
01
Overview
MPI-485520 is a preclinical-stage small molecule modulator of the interferon pathway, originally developed by Myriad Pharmaceuticals and later managed by its spin-off, Myrexis. The compound was designed to treat various autoimmune diseases by regulating the signaling pathways activated by interferons, which are often overexpressed or dysregulated in conditions such as systemic lupus erythematosus. Development of the asset was halted when Myrexis decided to suspend its research and development activities in early 2012 to explore strategic alternatives, eventually leading to the company's liquidation and the discontinuation of its internal pipeline.
Beyond the preview
Go deeper on MPI-485520.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MPI-485520.